Q1 2025 CRO Activity and Intel Report
Summary
This report offers an in-depth analysis of the contract research organization (CRO) industry, categorized by geography, therapeutic area, and phase of development for Q1 2025.Scope
- The Q1 CRO Activity and Intel report offers insights into CRO and sponsor activity, clinical trial trends, and geographical performance across various therapeutic areas.
Reasons to Buy
- This report will enable the user to answer the following questions:
- What are the trends by region, therapy area, sites by CROs for the past quarter?
- Who was the most active CRO in the past quarter?
- Who were the most active sponsors by market cap in the past quarter?
- What was the most widely studied therapy area in the past quarter vs. the previous year’s quarter?
- By region, who had the most clinical trials initiated in the past quarter?
- By region, what were the past quarter’s CRO invitations and appointments?
Table of Contents
- Introduction
- Global
- CRO and sponsor activity in Q1 2025
- Most-used CROs
- Most active large- and mega-cap sponsors
- Most active mid-cap sponsors
- Most active small-cap sponsors
- Clinical trials in oncology and CNS
- Therapeutic area breakdown of clinical trials initiated in Q1 2025 vs. Q1 2024
- Trials initiated in the 10 most active oncology indications in Q1 2025 vs. Q1 2024
- Trials initiated in the 10 most active CNS indications in Q1 2025 vs. Q1 2024
- Top 10 CROs by number of sites in Q1 2025
- North America
- Clinical trial activity in North America in Q1 2025
- Most active North American regions in Q1 2025 vs. Q1 2024
- Phase breakdown of trials initiated in North America in Q1 2025 vs. Q1 2024
- Therapeutic area breakdown of clinical trials initiated in North America in Q1 2025 vs. Q1 2024
- Top 10 trial sites by trials initiated in North America in Q1 2025
- Insights: CRO invites for sponsors based in North America
- Insights: CRO appointments for sponsors based in North America
- Europe
- Clinical trial activity in Europe in Q1 2025
- Most active European regions in Q1 2025 vs. Q1 2024
- Phase breakdown of trials initiated in Europe in Q1 2025 vs. Q1 2024
- Therapeutic area breakdown of clinical trials initiated in Europe in Q1 2025 vs. Q1 2024
- Top 10 trial sites by trials initiated in Europe in Q1 2025
- Insights: CRO invites for sponsors based in Europe
- Insights: CRO appointments for sponsors based in Europe
- Rest of the world
- Clinical trial activity in ROW in Q1 2025
- Most active regions in ROW in Q1 2025 vs. Q1 2024
- Phase breakdown of trials initiated in ROW in Q1 2025 vs. Q1 2024
- Therapeutic area breakdown of clinical trials initiated in ROW in Q1 2025 vs. Q1 2024
- Top 10 trial sites by trials initiated in ROW in Q1 2025
- Appendix
- Contact the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ICON
- Astrazeneca
- Akesobio
- CSPPC Pharmaceutical
- ImmunityBio
- Boryung
